Document Detail

Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
MedLine Citation:
PMID:  11253736     Owner:  NLM     Status:  MEDLINE    
A characteristic feature of patients with heterozygous familial hypercholesterolemia (FH) is the premature occurrence of coronary artery disease because of elevated LDL cholesterol levels. Hyperinsulinemia and insulin resistance, important characteristics of the cardiovascular dysmetabolic syndrome (CDS), were found to be associated with coronary artery disease in FH subjects, as in the general population. We investigated whether hypofibrinolysis, as part of CDS, is independently associated with symptomatic coronary artery disease in these high-risk patients. Clinical examination (body mass index, waist circumference, blood pressure) and blood analysis (plasma tissue plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI-1) antigen and activity, fibrinogen, serum lipids and lipoproteins, fasting glucose and insulin) were carried out in 39 male patients with heterozygous FH (aged 46.6 +/- 8.8 years). Insulin resistance was calculated using the homeostasis model assessment (HOMA) mathematical model. Thirteen of the patients had suffered a myocardial infarction (MI) 5 to 8 years ago (aged 47.8 +/- 6.1 years) and 26 were free of coronary artery disease (aged 45.9 +/- 9.9 years). There was no difference in total and LDL cholesterol between the two groups. Patients with previous myocardial infarction had significantly higher levels of insulin, insulin resistance, triglycerides, t-PA antigen, PAI-1 antigen and activity, and significantly lower values of HDL cholesterol. Other widely recognised risk factors for coronary artery disease, such as smoking, systolic and diastolic blood pressure, obesity and age, did not differ significantly between the groups. In the logistic regression model, PAI-1 antigen, as a marker of hypofibrinolysis, emerged as an independent risk factor for the occurrence of myocardial infarction (odds ratio 1.55; p = 0.02). In summary our results suggest that the impairment of fibrinolytic activity resulting from elevated levels of PAI-1 antigen and activity and t-PA antigen is an independent variable in CDS associated with the premature occurrence of myocardial infarction in male patients with FH.
M Sebestjen; B Zegura; B Guzic-Salobir; I Keber
Related Documents :
11427206 - Fibromuscular cap composition is important for the stability of established atheroscler...
18000966 - Is elevated high-density lipoprotein cholesterol always good for coronary heart disease?
11863326 - Management of intermittent claudication: the importance of secondary prevention.
18715656 - Beneficial effects of statin treatment after myocardial infarction: is progenitor cell ...
9491946 - Clinical and detailed angiographic findings in patients with ambulatory electrocardiogr...
16432676 - Ventricular unloading with a miniature axial flow pump in combination with extracorpore...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Wiener klinische Wochenschrift     Volume:  113     ISSN:  0043-5325     ISO Abbreviation:  Wien. Klin. Wochenschr.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-03-19     Completed Date:  2001-04-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  21620870R     Medline TA:  Wien Klin Wochenschr     Country:  Austria    
Other Details:
Languages:  eng     Pagination:  113-8     Citation Subset:  IM    
Department of Angiology, Hospital of Internal Medicine, University Clinical Centre, Ljubljana, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Body Mass Index
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Hyperlipoproteinemia Type II / blood,  complications*,  genetics*
Insulin / blood
Insulin Resistance*
Logistic Models
Middle Aged
Models, Theoretical
Myocardial Infarction / blood,  etiology*
Plasminogen Activator Inhibitor 1 / blood
Risk Factors
Sex Factors
Tissue Plasminogen Activator / blood
Triglycerides / blood
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Plasminogen Activator Inhibitor 1; 0/Triglycerides; 11061-68-0/Insulin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sepsis-associated purpura fulminans in adults.
Next Document:  Post-traumatic changes in insulin-like growth factor type 1 and growth hormone in patients with bone...